NicOx spikes on successful glaucoma drug study

Shares of France's NicOx spiked on the news that its experimental glaucoma drug licensed to Bausch & Lomb proved positive in a mid-stage study. According to their release two of the four doses used in the trial worked better than Pfizer's ($PFE) Xalatan to reduce eye-fluid pressure. The upbeat news is a welcome relief for NicOx, which was hammered last year after big regulatory setbacks in the U.S. and Europe for naproxcinod. Story